MCID: FLR001
MIFTS: 55

Filarial Elephantiasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Filarial Elephantiasis

MalaCards integrated aliases for Filarial Elephantiasis:

Name: Filarial Elephantiasis 12 53 15
Lymphatic Filariasis 12 76 53 59 55 3 15
Elephantiasis 53 73
Filariasis 53 73
Infection by Wuchereria Bancrofti 73
Wuchereria Bancrofti Infection 53
Bancroftian Filarial Chyluria 12
Malayi Tropical Eosinphilia 53
Bancroftian Elephantiasis 12
Elephantiasis of Eyelid 12
Elephantiasis, Filarial 44
Bancroftian Filariasis 53
Filarial Elephantiases 73
Wuchereriasis 53
Elephantitis 53

Characteristics:

Orphanet epidemiological data:

59
lymphatic filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12211
ICD10 33 B74.0
MeSH 44 D004605
NCIt 50 C128360
SNOMED-CT 68 91586009
Orphanet 59 ORPHA2035
ICD10 via Orphanet 34 B74.0 B74.1 B74.2
UMLS via Orphanet 74 C0013884

Summaries for Filarial Elephantiasis

NIH Rare Diseases : 53 Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms that only live in the human lymph system, which maintains the body's fluid balance and fights infections. It is spread from person to person by mosquitoes. Most infected people are asymptomatic and never develop clinical symptoms. A small percentage of people develop lymphedema, which may affect the legs, arms, breasts, and genitalia; bacterial infections that cause hardening and thickening of the skin, called elephantiasis; hydrocele (swelling of the scrotum) in men; and pulmonary tropical eosinophilia syndrome. Treatment may include a yearly dose of medicine, called diethylcarbamazine (DEC); while this drug does not kill all of the adult worms, it prevents infected people from giving the disease to someone else.

MalaCards based summary : Filarial Elephantiasis, also known as lymphatic filariasis, is related to filariasis and loiasis, and has symptoms including chyluria An important gene associated with Filarial Elephantiasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Th17 cell differentiation and NF-kappaB Signaling. The drugs Ivermectin and Albendazole have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and testes.

Disease Ontology : 12 A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.

CDC : 3 People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

Wikipedia : 76 Lymphatic filariasis, also known as elephantiasis, is a human disease caused by parasitic worms known as... more...

Related Diseases for Filarial Elephantiasis

Diseases related to Filarial Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 266)
# Related Disease Score Top Affiliating Genes
1 filariasis 34.0 IL10 IL5 TLR2 TLR9
2 loiasis 33.5 IL10 SRCIN1
3 elephantiasis 31.7 GPT2 SRCIN1
4 schistosomiasis 30.6 IL10 IL4 IL5
5 malaria 30.4 IL10 IL4 IL5 TLR2 TLR9
6 endomyocardial fibrosis 30.3 IL10 IL4
7 pulmonary eosinophilia 30.0 IL4 IL5
8 intestinal volvulus 29.8 IL5 SRCIN1
9 dermatitis 29.7 IL4 IL5 TLR9
10 tetanus 29.6 IL10 IL4 IL5
11 trypanosomiasis 29.5 IL10 IL4 TLR2 TLR9
12 chlamydia 29.5 IL10 IL4 TLR2
13 leishmaniasis 29.5 IL10 IL4 IL5 TLR2 TLR9
14 pulmonary tuberculosis 29.4 IL10 IL4 TLR2 TLR9
15 parasitic helminthiasis infectious disease 29.4 GPT2 IL10 IL4 IL5 SRCIN1 STH
16 parasitic protozoa infectious disease 29.3 IL10 IL4 TLR2 TLR9
17 visceral leishmaniasis 29.3 IL10 IL4 TLR2 TLR9
18 cutaneous leishmaniasis 29.1 IL10 IL4 IL5 TLR2 TLR9
19 podoconiosis 11.8
20 dirofilariasis 11.6
21 onchocerciasis 11.4
22 lymphedema 11.4
23 mansonelliasis 11.4
24 setariasis 11.0
25 dipetalonemiasis 11.0
26 eye lymphoma 10.3 IL10 TLR9
27 mucocutaneous leishmaniasis 10.2 IL10 TLR9
28 hydrocele 10.2
29 autoimmune disease of eyes, ear, nose and throat 10.2 IL10 TLR9
30 ascaridiasis 10.2 IL10 STH
31 trichuriasis 10.2 IL10 STH
32 cephalosporin allergy 10.2 IL10 IL5
33 necatoriasis 10.2 IL10 IL5
34 cow milk allergy 10.2 IL10 IL5
35 tropical endomyocardial fibrosis 10.2 IL10 IL4
36 hyperlucent lung 10.2 IL10 IL4
37 tungiasis 10.2 IL10 IL4
38 multicentric castleman disease 10.2 IL10 IL5
39 retinitis pigmentosa 22 10.2 IL10 IL4
40 baylisascariasis 10.2 IL10 IL4
41 castleman disease 10.2 IL10 IL5
42 nut allergy 10.2 IL5 TLR9
43 penicillin allergy 10.2 IL10 IL4
44 beta-lactam allergy 10.2 IL10 IL4
45 autoimmune gastritis 10.1 IL10 IL4
46 acanthocheilonemiasis 10.1
47 orofacial granulomatosis 10.1 IL10 IL4
48 buruli ulcer 10.1 IL10 IL4
49 bardet-biedl syndrome 15 10.1 IL10 IL4
50 lacrimal apparatus disease 10.1 IL10 TLR9

Graphical network of the top 20 diseases related to Filarial Elephantiasis:



Diseases related to Filarial Elephantiasis

Symptoms & Phenotypes for Filarial Elephantiasis

UMLS symptoms related to Filarial Elephantiasis:


chyluria

Drugs & Therapeutics for Filarial Elephantiasis

Drugs for Filarial Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 70288-86-7 6474909
2
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 54965-21-8 2082
3
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 90-89-1 3052
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 564-25-0 54671203
5
Azithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 83905-01-5 55185 447043
6
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 55268-74-1 4891
7 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
8 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Antimitotic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Anthelmintics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12 Lipoxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Antimalarials Phase 4,Phase 3,Phase 2
15 Anticonvulsants Phase 4
16
Petrolatum Approved, Investigational Phase 3 8009-03-8
17
Glycerol Approved, Investigational Phase 3 56-81-5 753
18 Disinfectants Phase 3
19 Protective Agents Phase 3
20 Eusol Phase 3
21 Sodium hypochlorite Phase 3
22 Vitamins Phase 3
23 Milbemycin Phase 3,Phase 2
24 Reslizumab Approved, Investigational Phase 2
25
Rifampicin Approved Phase 2 13292-46-1 5458213 5381226
26
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
27
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
28 Artemisinine Phase 2
29 Artemisinins Phase 2
30 Anti-Asthmatic Agents Phase 2
31 Antibodies, Monoclonal Phase 2
32 Antibodies Phase 2
33 Respiratory System Agents Phase 2
34 Immunoglobulins Phase 2
35 Antitubercular Agents Phase 2
36 Antibiotics, Antitubercular Phase 2
37 Cytochrome P-450 CYP3A Inducers Phase 2
38 Nucleic Acid Synthesis Inhibitors Phase 2
39 Imatinib Mesylate Phase 2 220127-57-1 123596
40 Protein Kinase Inhibitors Phase 2
41
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
42 Pharmaceutical Solutions Phase 1
43
Mebendazole Approved, Vet_approved 31431-39-7 4030
44
Piperazine Approved, Vet_approved 110-85-0 4837
45
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
46
Citric Acid Approved, Nutraceutical, Vet_approved 77-92-9 311
47
Suramin Investigational 145-63-1 5361
48 Citrate
49 Piperazine citrate
50 Liver Extracts Not Applicable

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy Completed NCT03052998 Phase 4 Ivermectin
5 Twice Yearly Treatment for the Control of LF Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
6 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 4 Albendazole
7 Cluster RCT of Co-administration Azithromycin, Albendazole & Ivermectin Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
8 Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
9 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis Withdrawn NCT02734186 Phase 4 Praziquantel
10 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
11 An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis Completed NCT02839772 Phase 3
12 IVM Alone vs ALB + IVM Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
13 Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
14 A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Recruiting NCT02927496 Phase 3 Doxycycline;Placebo
15 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka Recruiting NCT02929134 Phase 3 Doxycycline;Placebo
16 Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana Active, not recruiting NCT02078024 Phase 3 IVM plus ALB;IVM
17 A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Not yet recruiting NCT02929121 Phase 3 Doxycycline;Placebo
18 Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs ) Not yet recruiting NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
19 Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
20 Doxycycline to Treat Mansonella Perstans Infection in Patients With and Without Lymphatic Filariasis Completed NCT00340691 Phase 2 Doxycycline
21 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00339417 Phase 2 Albendazole;Ivermectin
22 Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
23 Effect of Albendazole Dose on Clearance of Filarial Worms Completed NCT00375583 Phase 2 DEC/Albendazole
24 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
25 Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
26 Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
27 Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness Completed NCT00127504 Phase 2 Rifampin;Azithromycin
28 Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana Completed NCT02281643 Phase 2 Doxycycline
29 PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Not yet recruiting NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
30 Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
31 Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn NCT01035619 Phase 2 moxidectin
32 Relative Bioavailability Study of Emodepside IR-tablets and Solution Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
33 First in Man Clinical Trial of Emodepside (BAY 44-4400) Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
34 Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside Recruiting NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
35 Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE) Active, not recruiting NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
36 Exhaled NO Testing in Filariasis Completed NCT01628497
37 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
38 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
39 Research for Elim of Filariasis Completed NCT00145223
40 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
41 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
42 Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
43 Interaction Between HIV and Lymphatic Filariasis Completed NCT00295698 Not Applicable Diethylcarbamazine
44 Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 Not Applicable 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
45 Medical Implications of Coinfection With Malaria and Filariasis Parasites Completed NCT00471666
46 Safety of the Co-administration of Three Drugs for Trachoma and Lymphatic Filariasis Elimination Completed NCT01586169 Not Applicable triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
47 Evaluation of Antibacterial Soap for Treatment of Lymphedema in a Filariasis-Endemic Area Completed NCT00139100 Not Applicable antimicrobial agent in soap
48 Prevalence of LF Infection in Districts Not Included in LF Control Activities Completed NCT03131401
49 Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis Completed NCT00344279
50 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523

Search NIH Clinical Center for Filarial Elephantiasis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: elephantiasis, filarial

Genetic Tests for Filarial Elephantiasis

Anatomical Context for Filarial Elephantiasis

MalaCards organs/tissues related to Filarial Elephantiasis:

41
Skin, Breast, Testes, T Cells, Eye, Bone, Heart

Publications for Filarial Elephantiasis

Articles related to Filarial Elephantiasis:

(show top 50) (show all 1037)
# Title Authors Year
1
A surveillance system for lymphatic filariasis after its elimination in Sri Lanka. ( 30308253 )
2019
2
An assessment of mosquito collection techniques for xenomonitoring of anopheline-transmitted Lymphatic Filariasis in Ghana. ( 29898803 )
2018
3
Perceptions, knowledge, attitudes and practices for the prevention and control of lymphatic filariasis in Conakry, Republic of Guinea. ( 29224979 )
2018
4
Understanding heterogeneities in mosquito-bite exposure and infection distributions for the elimination of lymphatic filariasis. ( 29386362 )
2018
5
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis. ( 29348597 )
2018
6
Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. ( 29444078 )
2018
7
Elimination of lymphatic filariasis as a public health problem from the Cook Islands. ( 29785168 )
2018
8
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. ( 29860672 )
2018
9
Elucidation of immunological response and its regulatory network by P-TUFT-ALT-2: a promising fusion protein vaccine for human lymphatic filariasis. ( 29892388 )
2018
10
Assessing knowledge about lymphatic filariasis and the implementation of mass drug administration amongst drug deliverers in three districts/cities of Indonesia. ( 29801511 )
2018
11
Prospects of developing a prophylactic vaccine against human lymphatic filariasis - evaluation of protection in non-human primates. ( 29885437 )
2018
12
Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review. ( 29907117 )
2018
13
Bilateral vulval filarial elephantiasis. ( 29472427 )
2018
14
Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis. ( 29916444 )
2018
15
Molecular xenomonitoring for post-validation surveillance of lymphatic filariasis in Togo: no evidence for active transmission. ( 29361964 )
2018
16
Integrated risk mapping and landscape characterisation of lymphatic filariasis and loiasis in South West Nigeria. ( 29774296 )
2018
17
Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models. ( 29860286 )
2018
18
Integrated morbidity mapping of lymphatic filariasis and podoconiosis cases in 20 co-endemic districts of Ethiopia. ( 29965963 )
2018
19
Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary? ( 29402636 )
2018
20
Island-Wide Surveillance of Gastrointestinal Protozoan Infections on Fiji by Expanding Lymphatic Filariasis Transmission Assessment Surveys as an Access Platform. ( 29405101 )
2018
21
Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. ( 29308790 )
2018
22
Community perspectives on persistent transmission of lymphatic filariasis in three hotspot districts in Ghana after 15 rounds of mass drug administration: a qualitative assessment. ( 29433461 )
2018
23
Progress on elimination of lymphatic filariasis in Sierra Leone. ( 29866207 )
2018
24
Cervical Lymphatic Filariasis in a Pediatric Patient: Case Report and Database Analysis of Lymphatic Filariasis in the United States. ( 29848402 )
2018
25
Evaluation of Treatment Coverage and Enhanced Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis in Five Local Government Areas Treating Twice Per Year in Edo State, Nigeria. ( 29943709 )
2018
26
Economic evaluations of lymphatic filariasis interventions: a systematic review and research needs. ( 29391042 )
2018
27
Protection of the house against Chagas disease, dengue, leishmaniasis, and lymphatic filariasis: a systematic review. ( 29074038 )
2018
28
Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis. ( 29149303 )
2018
29
Use of Antibody Tools to Provide Serologic Evidence of Elimination of Lymphatic Filariasis in The Gambia. ( 29165213 )
2018
30
How elimination of lymphatic filariasis as a public health problem in the Kingdom of Cambodia was achieved. ( 29463307 )
2018
31
Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa. ( 29471340 )
2018
32
Crystal structure of Brugia malayi venom allergen-like protein-1 (BmVAL-1), a vaccine candidate for lymphatic filariasis. ( 29501266 )
2018
33
Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa. ( 29522520 )
2018
34
The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia. ( 29530082 )
2018
35
Discovery of a Stress-Activated Protein Kinase Inhibitor for Lymphatic Filariasis. ( 29541362 )
2018
36
Results of a confirmatory mapping tool for Lymphatic filariasis endemicity classification in areas where transmission was uncertain in Ethiopia. ( 29579038 )
2018
37
Evaluation of the recombinant antigens Wb14 and WbT for the capture antibody diagnosis of lymphatic filariasis. ( 29590236 )
2018
38
Brugia malayi infection in ferrets - A small mammal model of lymphatic filariasis. ( 29601572 )
2018
39
Erratum to: "For as Long as Necessary: Examining 30 years of MSD's Focus on Achieving Elimination of Onchocerciasis and Lymphatic Filariasis". ( 29617827 )
2018
40
Status of lymphatic filariasis with progression of age and gender & eradication strategies: A survey among residents of Hardoi district of Uttar Pradesh, an endemic region of North India. ( 29642988 )
2018
41
Surveillance for lymphatic filariasis after stopping mass drug administration in endemic districts of Togo, 2010-2015. ( 29661231 )
2018
42
Chiluria in a lymphatic filariasis endemic area. ( 29720217 )
2018
43
Rapid progress towards elimination of lymphatic filariasis in endemic regions of Myanmar as a result of 16 years of anti-filarial activities (2001-2016). ( 29720887 )
2018
44
Lymphatic Filariasis Presenting as a Swelling over the Upper Arm: A Case Report. ( 29725519 )
2018
45
Morbidity management and disability prevention for lymphatic filariasis in Sri Lanka: Current status and future prospects. ( 29746479 )
2018
46
Lymphatic filariasis elimination programme in Assam, India, needs change in mass drug administration strategy to target the focus of infection. ( 29749354 )
2018
47
Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature. ( 29768412 )
2018
48
Inhibition efficiency of a newly isolated flavonoid compound from Vitex negundo L. leaves against cattle-endosymbiont Setaria cervi: Phytomedicine for lymphatic filariasis. ( 29988277 )
2018
49
Emotional Difficulties and Experiences of Stigma among Persons with Lymphatic Filariasis in Plateau State, Nigeria. ( 30008550 )
2018
50
Building Trust through Lymphatic Filariasis Elimination: A Platform to Address Social Exclusion and Human Rights in the Dominican Republic. ( 30008551 )
2018

Variations for Filarial Elephantiasis

Expression for Filarial Elephantiasis

Search GEO for disease gene expression data for Filarial Elephantiasis.

Pathways for Filarial Elephantiasis

Pathways related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.27 IL10 IL4 IL5 TLR2
2 12.22 IL10 IL4 TLR2 TLR9
3
Show member pathways
12.09 IL4 IL5 TLR2
4
Show member pathways
12 IL10 IL4 TLR2
5 11.95 IL10 TLR2 TLR9
6
Show member pathways
11.9 IL4 TLR2 TLR9
7
Show member pathways
11.78 IL10 TLR2 TLR9
8
Show member pathways
11.75 IL5 TLR2 TLR9
9 11.7 IL10 IL4 IL5
10 11.45 IL10 IL4 IL5
11 11.3 IL10 IL4 IL5
12 11.12 IL10 TLR9
13 11.12 IL10 TLR2 TLR9
14 11.09 IL4 IL5
15 11.06 IL4 IL5
16 10.99 IL10 IL4 IL5
17 10.94 IL10 IL4 IL5
18 10.59 IL10 IL4 IL5
19 10.21 IL10 IL4 IL5

GO Terms for Filarial Elephantiasis

Biological processes related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.85 IL10 IL5 TLR2 TLR9
2 immune response GO:0006955 9.8 IL10 IL4 IL5 TLR2 TLR9
3 negative regulation of endothelial cell apoptotic process GO:2000352 9.61 IL10 IL4
4 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.61 TLR2 TLR9
5 negative regulation of interleukin-6 production GO:0032715 9.6 IL10 TLR9
6 positive regulation of interleukin-8 production GO:0032757 9.59 TLR2 TLR9
7 positive regulation of interferon-beta production GO:0032728 9.58 TLR2 TLR9
8 positive regulation of interleukin-12 production GO:0032735 9.58 TLR2 TLR9
9 positive regulation of interleukin-10 production GO:0032733 9.57 TLR2 TLR9
10 positive regulation of chemokine production GO:0032722 9.56 TLR2 TLR9
11 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.54 TLR2 TLR9
12 regulation of cytokine secretion GO:0050707 9.52 TLR2 TLR9
13 I-kappaB phosphorylation GO:0007252 9.51 TLR2 TLR9
14 negative regulation of interleukin-8 production GO:0032717 9.49 IL10 TLR9
15 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL10 IL4
16 positive regulation of interleukin-18 production GO:0032741 9.46 TLR2 TLR9
17 tumor necrosis factor production GO:0032640 9.43 TLR2 TLR9
18 positive regulation of toll-like receptor signaling pathway GO:0034123 9.37 TLR2 TLR9
19 positive regulation of B cell proliferation GO:0030890 9.33 IL4 IL5 TLR9
20 regulation of isotype switching GO:0045191 9.32 IL10 IL4
21 type 2 immune response GO:0042092 9.26 IL10 IL4
22 asparaginyl-tRNA aminoacylation GO:0006421 8.96 NARS NARS2
23 response to molecule of bacterial origin GO:0002237 8.8 IL10 TLR2 TLR9

Molecular functions related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 IL10 IL4 IL5
2 growth factor activity GO:0008083 9.33 IL10 IL4 IL5
3 signaling pattern recognition receptor activity GO:0008329 8.96 TLR2 TLR9
4 asparagine-tRNA ligase activity GO:0004816 8.62 NARS NARS2

Sources for Filarial Elephantiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....